Results 181 to 190 of about 499,734 (317)

Plasma extrachromosomal circular DNA as a biomarker in EGFR‐targeted therapy of non‐small cell lung cancer

Molecular Oncology, EarlyView.
Detection of extrachromosomal circular DNA (eccDNA) in plasma samples from EGFR‐mutated non‐small cell lung cancer patients. Plasma was collected before and during treatment with the EGFR‐tyrosine kinase inhibitor osimertinib. Plasma eccDNA was detected in all cancer samples, and the presence of the EGFR gene on eccDNA serves as a potential biomarker ...
Simone Stensgaard, Sarmad Mehmood, Eva Boysen Fynboe Ebert, Peter Meldgaard, Anindya Dutta, Boe S. Sorensen   +5 more
wiley   +1 more source

Incidence and prognostic factors of self-harm and subsequent unnatural death in South Africa: A cohort study. [PDF]

PLoS Med
Skrivankova VW, Rabie S, Tlali M, Folb N, Chinogurei C, Bennett S, Wesso A, Ruffieux Y, Cornell M, Seedat S, Egger M, Davies MA, Maartens G, Joska J, Haas AD.   +14 more
europepmc   +1 more source

Survivin and Aurora Kinase A control cell fate decisions during mitosis

Molecular Oncology, EarlyView.
Aurora A interacts with survivin during mitosis and regulates its centromeric role. Loss of Aurora A activity mislocalises survivin, the CPC and BubR1, leading to disruption of the spindle checkpoint and triggering premature mitotic exit, which we refer to as ‘mitotic slippage’.
Hana Abdelkabir, Shalitha Wickrama Arachchige, Sally P. Wheatley   +2 more
wiley   +1 more source

Correction: Measuring sustainability of opioid agonist therapy programs in the context of transition from Global Fund Support

Harm Reduction Journal
Raminta Stuikyte, Ivan Varentsov, Catherine Cook, Sergii Dvoriak   +3 more
doaj   +1 more source

Do perceptions of the harm of heated tobacco products differ by smoking status? A cross-sectional analysis of the Japan Society and New Tobacco Internet Survey (JASTIS) 2020 in Japan. [PDF]

BMJ Public Health
Yuri K, Higashiyama A, Takemura S, Suzuki H, Bassole Epse Brou MAM, Zhang Y, Aono N, Tabuchi T, Fujiyoshi A.   +8 more
europepmc   +1 more source

Imperial strategy of cancer cells through mitochondrial transfer

Molecular Oncology, EarlyView.
Cangkrama et al. demonstrated that cancer cells donate their mitochondria to fibroblasts through mitochondrial transfer, reprogramming them into ‘MitoCAF’. Likewise, our group has identified mitochondrial transfer from cancer cells to tumor infiltrating lymphocytes, resulting in mitochondrial ‘hijack’ and impaired antitumor immunity.
Takamasa Ishino, Yosuke Togashi
wiley   +1 more source

Increasing opportunities for community input in harm reduction program development using iterative engagement. [PDF]

Harm Reduct J
Wagner NM, Carlson JA, Bean M, Wineland A, Blum J, Cardona SA, Covarrubias S, Kempe A, King AC, Huebschmann AG.   +9 more
europepmc   +1 more source

Absurd Emphasis on Effectiveness and Immediate Results Will Harm Medical Treatment [PDF]

, 1997
Töres Theorell
openalex   +1 more source

CDK11 inhibition induces cytoplasmic p21WAF1 splice variant by p53 stabilisation and SF3B1 inactivation

Molecular Oncology, EarlyView.
CDK11 inhibition stabilises the tumour suppressor p53 and triggers the production of an alternative p21WAF1 splice variant p21L, through the inactivation of the spliceosomal protein SF3B1. Unlike the canonical p21WAF1 protein, p21L is localised in the cytoplasm and has reduced cell cycle‐blocking activity.
Radovan Krejcir, Lukasz Arcimowicz, Lucia Martinkova, Vaclav Hrabal, Filip Zavadil Kokas, Tomas Henek, Martina Kucerikova, Ondrej Bonczek, Pavlina Zatloukalova, Lenka Hernychova, Philip J. Coates, Borivoj Vojtesek, David P. Lane   +12 more
wiley   +1 more source

The rapidly growing landscape of RAS inhibitors: from selective allele blockade to broad inhibition strategies

Molecular Oncology, EarlyView.
RAS‐targeted therapies have become a clinical reality. Although promising results in patients have been achieved, there are still challenges ahead such as coping with drug resistance. Here we summarize selected RAS inhibitors targeting either individual KRAS mutant isoforms (KRASG12C, KRASG12D, KRASG12V) or exhibiting a wider inhibitory spectrum ...
Matthias Drosten, Mariano Barbacid
wiley   +1 more source